Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | AR | P10275 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674670 | 0.86 | AR (0.84) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL7203008 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2ARRAB9AL3MBTL1NPC1 | |
| SCHEMBL2555926 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL18674598 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL18674660 | 0.84 | MAPT (0.77) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL18674671 | 0.83 | AR (0.97) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL3816958 | 0.82 | RAB9A (0.73) | SMN1; SMN2ARTP53ALOX15RAB9A | |
| SCHEMBL12291571 | 0.82 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9AL3MBTL1NPC1MEN1 | |
| SCHEMBL18674667 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2ARTP53HSD17B10ALOX15 | |
| SCHEMBL17266249 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ARTP53HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912595-B | Compound containing thiazole or thiadiazole structure and application thereof | 中国药科大学 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023061051-A1 | SULFAMIDE USP8 INHIBITOR AND USE THEREOF | 中国药科大学 | 2023-04-20 | — | — | WO | disclosed |
| CN-113912595-A | Compound containing thiazole or thiadiazole structure and application thereof | 中国药科大学 | 2022-01-11 | — | — | CN | disclosed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | L'OREAL (FR) | 2017-03-30 | — | — | US | disclosed |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | L'OREAL (FR) | 2017-03-30 | — | — | US | disclosed |
| EP-1296974-B1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | KRT18, F12, CBR3 | SMN1; SMN2 4516/4885AR 562/4885TP53 1902/4885 |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | SMN1; SMN2 2692/4885AR 2919/4885TP53 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.